罗沙司他治疗免疫性血小板减少症的潜力:一项孟德尔随机化分析
本研究采用孟德尔随机化分析评估罗沙司他对免疫性血小板减少症(ITP)的治疗效果与安全性。结果显示罗沙司他与ITP风险降低相关(比值比0.79,95%CI 0.66-0.95,P=0.01),且39种潜在不良反应风险未见显著增加,提示其作为ITP治疗选择的潜力,需进一步研究。
要点
- 孟德尔随机化分析显示罗沙司他与ITP风险降低相关,比值比0.79(95%CI 0.66-0.95,P=0.01)。
- 基于EGLN1表达数量性状位点的分析显示39种潜在不良反应风险未见显著增加。
- 作者认为罗沙司他对ITP具有潜在保护作用,需进一步研究。
核心结论
- 罗沙司他对ITP显示出潜在保护作用,且不增加不良结局风险,提示其作为ITP治疗选择的潜力,需进一步研究。
研究设计与样本
- 采用孟德尔随机化分析,使用罗沙司他靶基因EGLN1、EGLN2和EGLN3的表达数量性状位点数据,以及来自Open Genome-Wide Association Study项目的ITP和不良结局遗传关联数据。
- 孟德尔随机化分析包括逆方差加权、MR-Egger回归、加权中位数和MR多效性残差和离群值方法以评估多效性,并使用Cochran Q统计量和I2 measure进行异质性评估与敏感性分析。
- 进行Meta分析以整合多个文献来源的效应量。
主要发现
- 孟德尔随机化分析显示罗沙司他与ITP风险降低显著相关(比值比0.79;95%CI 0.66-0.95;P=0.01),无水平多效性证据。
- Meta分析证实罗沙司他对ITP的保护作用。
- 利用罗沙司他靶基因EGLN1的表达数量性状位点作为工具变量,对39种潜在不良反应的孟德尔随机化分析显示风险未见显著增加。
关键数值与推荐
- 罗沙司他与ITP风险的比值比为0.79(95%CI 0.66-0.95;P=0.01)。
- 基于EGLN1表达数量性状位点的分析纳入39种潜在不良反应,未见风险显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impaired megakaryocyte maturation. Hypoxia-inducible factor-1α (HIF-1α), pivotal in the development of megakaryocytes and immune regulation, is downregulated in ITP. Roxadustat, which stabilizes HIF-1α, has emerged as a potential therapeutic drug for ITP that acts by enhancing HIF-1α-mediated megakaryocyte development and modulating immune responses. OBJECTIVES: This study evaluates the safety profile of roxadustat and its therapeutic efficacy for ITP treatment using Mendelian randomization (MR) analysis. METHODS: We used expression quantitative trait loci data for roxadustat's target genes (EGLN1, EGLN2, and EGLN3) and genetic associations with ITP and adverse outcomes from the Open Genome-Wide Association Study project. MR analysis included inverse-variance weighted, MR-Egger regression, weighted median, and MR pleiotropy residual sum and outlier methods to evaluate pleiotropy. Heterogeneity was assessed using Cochran's Q statistic and I2 measure with sensitivity analyses. A meta-analysis was performed to integrate effect sizes from multiple literature sources. RESULTS: MR analysis revealed a significant association between roxadustat and reduced ITP risk (odds ratio, 0.79; 95% CI, 0.66-0.95; P = .01) with no evidence of horizontal pleiotropy. Meta-analysis confirmed the protective effect of roxadustat on ITP. Utilizing the expression quantitative trait loci of roxadustat's target gene EGLN1 as instrumental variables, an MR analysis of 39 potential adverse reactions revealed no significant increase, suggesting a favorable safety profile for roxadustat. CONCLUSION: Roxadustat demonstrates a potential protective effect against ITP without increasing the risk of adverse outcomes, suggesting its promise as a therapeutic option for ITP and warranting further investigation.
引用
- Ma J, Hu Y, Dong S, et al. Therapeutic potential of roxadustat in immune thrombocytopenia: a Mendelian randomization analysis. J Thromb Haemost. 2025. PMID: 39756656. doi:10.1016/j.jtha.2024.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。